First Patient Treated with LC Bead LUMI™ Radiopaque Embolic Bead Supported by Philips Live Image Guidance

PhilipsBTG plc (LSE: BTG), a global specialist healthcare company, and Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in image-guided therapy, announced a significant milestone in their collaboration with the treatment of the first liver cancer patient with LC Bead LUMI™ in conjunction with Philips live image guidance, targeting a hypervascular tumor with the goal to block blood flow to achieve tumor necrosis.

Liver cancer is the second leading cause of cancer deaths in the world [1], and one of the most challenging to treat. Each year, more than 700,000 patients worldwide are diagnosed with liver cancer [2]. Interventional embolization is an option for some patients with tumors that cannot be removed by surgery.

The first patient treated signals the next stage in commercializing next generation embolic beads, which can be visualized during interventional procedures, allowing enhanced visualization to evaluate completeness of tumor treatment. As a result of the collaboration between BTG and Philips, for the first time doctors will be able to see rather than assume the location of the LC Bead LUMI™, in order to deliver their treatment with more confidence when treating liver cancer.

"The aim with this new radiopaque embolic bead and visualization technology is to provide clinicians like me the ability to make real-time adjustments while conducting the embolization procedure, so that we can optimize patients' treatment and hopefully improve targeting accuracy," said Bradford Wood, M.D., Director of the NIH Center for Interventional Oncology [3] and Chief of Interventional Radiology. "It is reassuring for the clinician and the patient to know that the treatment was delivered exactly where it was aimed, and where it was needed. Treating the first patient using LC Bead LUMI™ in combination with dedicated Philips 2D X-ray and 3D CBCT image guidance is a milestone in our public-private partnership with both of our industry research partners. The imaging of the beads during this first procedure was exquisite and provided valuable information."

By enabling visualization of beads during an embolization procedure, LC Bead LUMI™ will help embolization technology achieve its full potential. LC Bead LUMI™ has been developed with revolutionary radiopacity technology in collaboration with Philips that enables real-time visualization of bead location during embolization. LC Bead LUMI™, supported by Philips live image guidance, has the potential to offer interventional radiologists more control, allowing enhanced visualization to evaluate the completeness of tumor treatment and end-point determination.

"BTG continues to advance its leadership in Interventional Medicine by actively listening to our customers and providing creative solutions to meet their clinical needs," said Peter Pattison, Interventional Oncology General Manager, BTG. "Several years ago, we began scientific collaboration with Philips to evaluate the benefits of better image-guided therapy and this venture resulted in the ability to calibrate Philips' imaging software to LC Bead LUMI™. The clinical impact of the BTG-Philips collaboration is now helping interventional radiologists and multi-disciplinary teams make enhanced treatment decisions for patients with liver cancer."

"Minimally-invasive therapy procedures provide key benefits for healthcare systems and patients, and intelligent image guidance is an essential part of these procedures," said Ronald Tabaksblat, Business Leader Image Guided Therapy Systems at Philips. "We aim to continuously improve Image Guided Therapy and our collaboration with BTG to provide enhanced visibility and guidance during interventional embolization procedures is another important milestone in this exciting journey to help deliver excellent treatment and enhanced patient care."

LC Bead LUMI™ was cleared for clinical use in the US in December 2015 after extensive laboratory testing based on the clinical foundation of its predicate device, LC Bead®.

Related news articles:

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being company, focused on improving people’s lives through meaningful innovation in the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the Netherlands, Philips posted 2015 sales of EUR 24.2 billion and employs approximately 104,000 employees with sales and services in more than 100 countries. The company is a leader in cardiac care, acute care and home healthcare, energy efficient lighting solutions and new lighting applications, as well as male shaving and grooming and oral healthcare.

About BTG Interventional Medicine
BTG Interventional Medicine is part of BTG plc, a growing international specialist healthcare company. As medicine moves from major surgery to minor procedure, from the systemic to the local, no company endeavors to do more than BTG Interventional Medicine to help doctors in their quest to see more, reach further and treat smarter. Our growing portfolio of Interventional Medicine products is designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots, and varicose veins.

About LC Bead LUMI™
LC Bead LUMI™ is the first commercially available radiopaque embolic bead cleared by the US Food & Drug Administration (FDA) for the embolization of hypervascular tumors and arteriovenous malformations (AVMs). LC Bead LUMI™ provides visible confirmation of bead location during AVM procedure. The lasting radiopacity of LC Bead LUMI™ means they will also be visible in follow-up scans.

1. World Health Organization (WHO). Cancer factsheet. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed January 25, 2016.
2. American Cancer Society. What are the key statistics about liver cancer?. Available at: http://www.cancer.org/cancer/livercancer/detailedguide/liver-cancer-what-is-key-statistics. Last accessed January 25, 2016.
3. NIH does not endorse or recommend any commercial products, processes, or services. The views and opinions of authors expressed here do not necessarily state or reflect those of the US Government or the NIH, and they may not be used for advertising or product endorsement purposes.

Most Popular Now

Kick-off Meeting for eHealth Hub: An Int…

The Kick-off Meeting of the eHealth Hub project took place on the 20th and 21st of October 2016, in Murcia (Spain). The meeting effectively launched the activities of a newly...

Read more

HIV Test Performed on USB Stick

Scientists have developed a type of HIV test on a USB stick. The device, created by scientists at Imperial College London and DNA Electronics, uses a drop of blood to...

Read more

Philips and Masimo Sign Multi-Year Busin…

Royal Philips (NYSE: PHG; AEX: PHIA) and Masimo Corporation (NASDAQ: MASI) today announced a wide-ranging, multi-year business partnership involving both companies' innovations in patient monitoring and therapy solutions. The partnership...

Read more

Major Health IT Event Opens with Recogni…

21 - 22 November 2016, Barcelona, Spain. The World of Health IT (WoHIT) has opened its doors to over 1,000 healthcare IT professionals from across 25 different countries worldwide. Covering a...

Read more

Emergency Video Telemedicine Positively …

Approximately 10 percent of newborns require help breathing after birth, and 1 in 1,000 newborns require more intensive resuscitation measures. These infrequent, high-risk deliveries may present challenges to community hospitals...

Read more

Frontiers Health 2016

17 - 18 November 2016, Berlin, Germany. Healthcare is being transformed and to a good extent will be disrupted by digital technologies. Frontiers Health has been designed to provide a unique...

Read more

Crack the Human Brain

The time is ripe, the communication technology is available, for teams from different labs and different countries to join efforts and apply new forms of grassroots collaborative research in brain...

Read more

EC Open Call SC1-PM-15-2017: Personalise…

The activity aims at developing and validating radically new ICT based concepts and approaches for empowering and motivating people in need of guidance and care due to age related conditions...

Read more

MEDICA and COMPAMED 2016 Provide a Power…

14 - 17 November 2016, Düsseldorf, Germany. Once again, the world's biggest medical trade fair MEDICA and the leading international supplier trade fair COMPAMED, which take place in Düsseldorf, have provided...

Read more

Open Call SC1-HCO-08-2017: Actions to Br…

Despite serious efforts deployed at national and European level, the European Union sees significant internal disparities in terms of research and innovation performance as also identified in the Innovation Union...

Read more

Chronically Ill Women Underusing Online …

Barriers to internet use may be preventing chronically ill middle-aged and older women from being as healthy as they otherwise could be, new research suggests. The study conducted by researchers...

Read more

MEDICA 2016 + COMPAMED 2016 with over 5…

14 - 17 November 2016, Düsseldorf, Germany. When top decision-makers in the healthcare business meet in Düsseldorf again in the middle of November at the world's leading medical trade fair, MEDICA...

Read more
(HEALTH IT) SPACE - Take a look at who has just Joined